 |
|
Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
April 28, 2008A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.
In a late-breaking abstract presented at the 1st European Lung Cancer Conference jointly organized by the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO), Prof. Giorgio Scagliotti from the University of Torino, Italy presented data from the clinical trial stopped in February.
For some patients, the drug results in worse outcomes. "Based on a planned interim analysis the study showed a clear inferiority from adding sorafenib to carboplatin/paclitaxel in first-line non-small-cell lung cancer patients with squamous histology," Prof. Scagliotti said.
Sorafenib is an oral multikinase inhibitor with anti-angiogenic and antiproliferative activity. The drug, marketed as Nexavar by Bayer, is already approved for use in more than 40 countries for liver cancer and more than 70 countries for renal cell cancer.
The latest trial included 926 patients with unresectable stage IIIB/IV non-small-cell lung cancer who had received no prior systemic treatment. Patients were randomized to receive carboplatin plus paclitaxel, combined with either sorafenib 400 mg or placebo.
After a formal review of the ongoing study, the trial's data monitoring committee recommended termination. Preliminary results showed a median overall survival of 10.7 months in the sorafenib group vs 10.6 months in the placebo arm. Sorafenib-treated patients with squamous-cell non-small-cell lung cancer had a greater mortality rate than those with non-squamous histology.
"To date there is no evidence of any detrimental effect from sorafenib in additional subgroups of patients," Prof. Scagliotti said.
He noted that researchers are still studying the drug in lung cancer, including an ongoing study examining adding it to the combination of cisplatin and gemcitabine.
European Society for Medical Oncology
Sorafenib is an oral multikinase inhibitor with anti-angiogenic and antiproliferative activity. The drug, marketed as Nexavar by Bayer, is already approved for use in more than 40 countries for liver cancer and more than 70 countries for renal cell cancer.
The latest trial included 926 patients with unresectable stage IIIB/IV non-small-cell lung cancer who had received no prior systemic treatment. Patients were randomized to receive carboplatin plus paclitaxel, combined with either sorafenib 400 mg or placebo.
After a formal review of the ongoing study, the trial's data monitoring committee recommended termination. Preliminary results showed a median overall survival of 10.7 months in the sorafenib group vs 10.6 months in the placebo arm. Sorafenib-treated patients with squamous-cell non-small-cell lung cancer had a greater mortality rate than those with non-squamous histology.
"To date there is no evidence of any detrimental effect from sorafenib in additional subgroups of patients," Prof. Scagliotti said.
He noted that researchers are still studying the drug in lung cancer, including an ongoing study examining adding it to the combination of cisplatin and gemcitabine.
European Society for Medical Oncology
Lung Cancer News and Current Lung Cancer Events RSSAfrican-Americans have unique lung cancer risks from chronic obstructive pulmonary disease
Scientists at the M.D. Anderson Cancer Center have developed a risk prediction assessment for lung cancer specifically for African Americans that suggests a greater risk from chronic obstructive pulmonary disease (COPD).
Breaking the 'mucus barrier' with a new drug delivery system
Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.
Newly detected air pollutant mimics damaging effects of cigarette smoke
A previously unrecognized group of air pollutants could have effects remarkably similar to harmful substances found in tobacco smoke, Louisiana scientists are reporting in a study scheduled for presentation today at the 236th National Meeting of the American Chemical Society.
Targeted radiation therapy can control limited cancer spread
Precisely targeted radiation therapy can eradicate all evidence of disease in selected patients with cancer that has spread to only a few sites, suggests the first published report from an ongoing clinical trial.
Experimental chemotherapy regimen shows promise in treating advanced lung cancer
A combination of chemotherapy agents that have been tested in other tumor types appears to be a promising alternative to standard treatment for advanced non-small cell lung cancer, according to a report in the August 15 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.
If your first cigarette gave you a buzz and you now smoke, a gene may be to blame
Anyone who has ever tried smoking probably remembers that first cigarette vividly. For some, it brought a wave of nausea or a nasty coughing fit. For others, those first puffs also came with a rush of pleasure or "buzz."
Gene panel predicts lung cancer survival, study finds
Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment.
Vitamin A pushes breast cancer to form blood vessel cells
Researchers at Georgetown University Medical Center have discovered that vitamin A, when applied to breast cancer cells, turns on genes that can push stem cells embedded in a tumor to morph into endothelial cells. These cells can then build blood vessels to link up to the body's blood supply, promoting further tumor growth.
Patients unaware of link between smoking and bladder cancer
Even though cigarette smoking accounts for up to half of all bladder cancer cases, few people are aware of the connection - including more than three-quarters of patients who have bladder cancer.
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston.
More Lung Cancer News Articles
 | How to Survive Lung Cancer - A Practical 12-Step Plan by Michael Lloyd Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer... |
 | Lung Cancer: Myths, Facts, Choices--and Hope by Claudia I. Henschke, Peggy McCarthy, Sarah Wernick Winner of the 2003 American Society of Journalists and Authors' June Roth Memorial Award for Health and Medical Books. An authoritative book with new lifesaving strategies for those at risk and those already diagnosed. Lung cancer kills more women than breast cancer, more men than prostate cancer—because it's usually found too late. Claudia Henschke's groundbreaking research on early... |
 | Quick Facts on Lung Cancer (Quick Facts) by American Cancer Society Educate yourself about lung cancer What are your risk factors for lung cancer? Can you prevent it? How is lung cancer treated? What should you ask your doctor? QuickFACTS Lung Cancer is both a comprehensive and a quick read, with highlighted cover tabs for quick reference of specific topics. QuickFACTS Lung Cancer: Covers everything from risk factors to living well after cancer treatment ... |
 | Surviving Cancer by Margie Levine When cancer specialists at Boston’s internationally renowned Dana-Farber Cancer Institute diagnosed Margie Levine with a deadly asbestos-related lung cancer, they predicted that she had only six months to live. Refusing to give up hope, she chose an approach that combined state-of-the-art medicine with her own holistic program. Eleven years later, her mind/body regimen has evolved into a... |
 | Voices of Lung Cancer: The Healing Companion: Stories for Courage, Comfort and Strength (Voices Of series) Provided by the patients, their friends, families, and caregivers of those diagnaosed with lung cancer, these very personal stories offer inspired insight into the ways families and professionals care for both themselves and the patient, gain a deeper understanding of the relationships, and learn to come to terms with the end of life. Included are essays by medical experts about the science of... |
 | 100 Questions & Answers About Lung Cancer (100 Questions & Answers about . . .) by Karen Parles, Joan H. Schiller This book deals with lung cancer from a doctor's perspective and a patient's... |
 | What to Eat if You Have Cancer by Daniella Chace, Maureen Keane, John A. Lung Information on choosing the best foods to help combat the disease as well as the side effects of chemical, surgical, and radiation... |
 | Lung Cancer (Contemporary Issues in Cancer Imaging) Despite the world-wide drive to increase awareness of the risks of smoking, lung cancer remains a global problem. A multidisciplinary team approach is now considered the most effective way to manage lung cancer. Imaging plays a central role in this multidisciplinary approach; this is reflected in the present volume. Individual chapters focus on imaging (including screening, diagnosis of... |
 | Lung Cancer Lung cancer remains the leading cause of cancer-related death in men, and in women, it has surpassed even breast cancer. According to the American Cancer Society, in 2001, there will be about 169,500 new cases of lung cancer in the United States: 90,700 among men and 78,800 among women. LUNG CANCER is the second installment in the M. D. Anderson Cancer Care Series, featuring the current standard... |
| 100 Questions & Answers About Lung Cancer by Karen Parles, Joan H. Schiller |
| © 2008 BrightSurf.com |